Oncology
Oncology Augmented response endpoints and scientific rigour for early-phase solid tumour programs where standard RECIST measures do not tell the full story.
Why imaging demands a different approach.
Early-phase imaging is indication-specific. Fidēs designs endpoints around the biology your study needs to resolve.
Where we have experience.
Describe the imaging support Fidēs provides for this indication.
How Fidēs designs imaging endpoints around the biology of this indication.
In practice.
Oncology Uterine Contractility as a Quantitative Endpoint in Early-Phase Gynaecology Trials
Establishing uterine contractility as a quantitative, reproducible imaging endpoint for early-phase gynaecology trials.
Read case study
Oncology Beyond RECIST: Additive Imaging Endpoints in Solid Tumour Trials
How augmented endpoint analysis provides earlier and more interpretable signals than standard volumetric measures alone.
Read case study
Oncology Live Data Visibility in Phase I Imaging Trials
A review of how real-time imaging access changes sponsor behaviour and supports earlier go / no-go decisions in early development.
Read case studyTrusted by biopharma and biotech.
From emerging biotech to established pharma, we partner with teams where imaging insight matters most.
Gastroenterology
Fidēs' native scientific home. A decade of GI imaging expertise — IBD, motility disorders, hepatic disease and NASH — with proprietary tools for quantifying movement and function beyond standard sMARIA and MaRIA scoring.
Explore
Women’s Health
Cardiac function, vasomotion and structural assessment for early development programs requiring imaging insight beyond traditional measures.
Explore
Rheumatology
Structural and functional neuroimaging support for early-phase CNS and neurodegeneration programs.
Explore
Systemic/Chronic
Quantitative renal imaging — structure, function and perfusion — for early-phase nephrology and chronic kidney disease studies.
Explore